Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Depreciation (2016)

Viridian Therapeutics, Inc.\DE (VRDN) has 3 years of Accumulated Depreciation data on record, last reported at $881000.0 in Q3 2016.

  • For Q3 2016, Accumulated Depreciation rose 27.31% year-over-year to $881000.0; the TTM value through Sep 2016 reached $881000.0, up 27.31%, while the annual FY2015 figure was $739000.0, N/A changed from the prior year.
  • Accumulated Depreciation reached $881000.0 in Q3 2016 per VRDN's latest filing, up from $786000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $881000.0 in Q3 2016 and bottomed at $517466.0 in Q3 2014.
  • Average Accumulated Depreciation over 3 years is $694352.3, with a median of $692000.0 recorded in 2015.
  • Peak YoY movement for Accumulated Depreciation: surged 33.73% in 2015, then grew 27.31% in 2016.
  • A 3-year view of Accumulated Depreciation shows it stood at $517466.0 in 2014, then soared by 42.81% to $739000.0 in 2015, then rose by 19.22% to $881000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $881000.0 in Q3 2016, $786000.0 in Q1 2016, and $739000.0 in Q4 2015.